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INTRODUCTION
Malignant melanomas of the mucosal regions of the
head and neck are extremely rare neoplasms accounting
for less than 1% of all melanomas1. Approximately
half of all head and neck melanomas occur in the oral
cavity, followed by the nasal cavity (44%) and sinuses
(8%)2. The most frequent sites in the oral cavity are the
hard palate (more than 40%) and the gingiva2.
Melanomas arise from the uninhibited proliferation
of melanocytes found in the basal layer of the oral
mucous membranes3.  The clinical presentation of this
neoplasm varies widely, from a typically pigmented
macular or nodular lesion, to a non-pigmented
neoplasm that may be solitary or multiple, primary or
metastatic4. Less than 2% of all melanomas lack
pigmentation, in the oral mucosa however, up to 75%
of cases are amelanotic5, 6, 7.
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ABSTRACT
Malignant melanomas of the mucosal regions of the head and neck are
extremely rare neoplasms accounting for less than 1% of all melanomas.
Approximately half of all head and neck melanomas occur in the oral
cavity. Less than 2% of  all melanomas lack pigmentation, in the oral
mucosa however, up to 75% of  cases are amelanotic.
No etiologic factors or risk factors have been recognized for oral
melanomas. Some authors have suggested that oral habits and self-
medication may be of etiological significance. Oral melanoma is rare
but it is relatively frequent in countries like Japan, Uganda, and India. It
is rarely identified under the age of 20 years. In Australia where cutaneous
melanomas are relatively common primary melanoma of  the oral mucosa
is rare.
The surface architecture of oral melanomas ranges from macular to
ulcerated and nodular. The lesion is said to be asymptomatic in the early
stages but may become ulcerated and painful in advanced lesions.
The diagnosis of amelanotic melanoma is more difficult than that of
pigmented lesions. The neoplasm consists of spindle-shaped cells with
many mitotic figures and no cytoplasmic melanin pigmentation.
Immunohistochemistry using S-100, HMB-45, Melan-A and MART-1
will help in establishing the correct diagnosis.
Radical surgery with ample margins and adjuvant chemotherapy are
appropriate management protocol for malignant melanoma.
Oral melanoma is associated with poor prognosis but its amelanotic
variant has even worse prognosis because it exhibits a more aggressive
biology and because of difficulty in diagnosis which leads to delayed
treatment.
In contrast to cutaneous melanomas, which may
present with a horizontal or vertical growth pattern,
oral melanomas usually present typically with vertical
growth, thus spreading to contiguous sites early8. The
prognosis for oral melanomas is poor, with an overall
5-year survival rate of  15%8.
Etiology
In oral mucosa, melanocytes are located along the tips
and peripheries of  the rete pegs. No etiologic factors
have been recognized for oral melanomas. Risk factors
have also remained obscure. There appears to be no
geographic variations and only minor ethnic and gender
differences9. Some oral melanomas are believed to
originate from junctional nevis, others are thought to
arise from pre-existing Hutchinson’s malignant lentigo10.
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Some authors have suggested that oral habits and self-
medication may be of etiological significance in some
Indian and African groups11. According to Tanaka et
al12, the biological behavior of melanoma may be
related to the expression of  the proteins Rb, pRb2/
p130, p53 and p16, which may be helpful in predicting
the manifestation of this neoplasm, including the
melanin content.
Epidemiology
Oral melanoma is rare but it is relatively frequent in
countries like Japan, Uganda, and India13. Oral
melanoma is a lesion of adulthood, rarely identified
under the age of  20 years. In a study, the highest
incidence of malignant melanoma was reported in the
fifth to eight decades of life14. Hicks and Flaitz8 in a
review of oral malignant melanoma showed a male
predilection and an age range of 22 to 83 years, with
a mean age of  56 years. There is a higher incidence of
melanoma of the oral mucosa among Japanese than
Caucasians15. According to an African research, 1.7%
of all melanomas in Sudan occurred in the oropharynx
and 0.9% of the melanomas in Nigeria originated
within the oral cavity11. In Australia where cutaneous
melanomas are relatively common primary melanoma
of the oral mucosa is rare 14.
Clinical features
The surface architecture of oral melanomas ranges
from macular to ulcerated and nodular9.  Indeed
clinically, the tumors are classified into five types: I -
pigmented nodular, II – non-pigmented nodular, III
- pigmented macular, IV - pigmented mixed, and V –
non-pigmented mixed type16. The lesion is said to be
asymptomatic in the early stages but may become
ulcerated and painful in advanced lesions17.
Histology
The diagnosis of amelanotic melanoma is more
difficult than that of pigmented lesions18. Histological
description of a specimen by Notani et al19 showed
that the neoplasm consisted of spindle-shaped cells
with many mitotic figures and there was no
cytoplasmic melanin pigmentation. These malignant
cells possess considerable pleomorphism, with large,
irregular hyperchromatic nuclei and prominent
nucleoli8. Others have reported pleomorphic epithelioid
cells with bizarre nuclei, large cherry-red nucleoli,
occasional nuclear pseudo-inclusions and variable
amounts of dusty cytoplasmic pigment20.
Diagnosis
Lesions that are suspected to be melanomas should
be assessed both histologically and by immuno-
histochemistry, which are helpful in the diagnosis of
amelanotic melanoma and only slightly pigmented
melanoma21, 22. The immunohistochemical techniques
using S-100, HMB-45, Melan-A and MART-1 will help
in establishing the correct diagnosis21.
Treatment
Notani et al19 suggests a combination of  radical surgery
with ample margins and adjuvant chemotherapy as an
appropriate management protocol for malignant
melanoma. Many chemotherapy agents have been used
for malignant melanomas but dacarbazine was reported
to have the best response rate of about 20% as a single
agent23. The addition of the immunomodulator, OK-
432, injected around the neoplasm has been advocated
for treatment and prolonging survival periods in oral
lesions24.
Radiotherapy has been considered to have only a
palliative role and on its own was reported to be
ineffective since the lesion is not very radiosensitive25.
On the other hand, Tanaka et al.16 found radiotherapy
to be more successful than surgery for oral melanoma.
The treatment of amelanotic melanoma does not differ
in anyway from the pigmented neoplasm.
Prognosis
Lymphatic metastasis at the time of diagnosis seems
to be the best prognostic factor for oral melanoma26.
Rogers and Gibson22 reported that half of all patients
with oral melanoma had regional lymph node
metastases and 20% had disseminated melanomas at
initial assessment. The prognosis of amelanotic
melanoma tends to be poorer 18. Indeed, Nandapalan
et al.25 in a review of 257 mucosal melanomas of the
head and neck region reported that amelanotic
melanomas had a 20% survival at 3 years, whereas
pigmented melanoma had a 58% survival at 3 years.
This has resulted in part from delays in determining a
definitive diagnosis and initiating treatment. Poor
prognosis may also be due to the fact that amelanotic
lesions tend to exhibit vertical growth pattern while
the pigmented lesion showed a more radial growth
pattern. Ohashi et al.21 reported that of eight oral
melanomas without a radial growth pattern, only one
presented as a melanotic type, whereas 18 of 27 with
a radial growth patterns were melanotic. Vertical
growth will lead to early involvement of contiguous
structures and worsen the overall outcome. Milton also
drew attention to the fact that fast-growing melanomas
often have relatively less pigment than slow-growing
ones 27.
CONCLUSION
Oral melanoma is a relatively rare neoplasm associated
with poor prognosis but its amelanotic variant has even
worse prognosis because it exhibits a more aggressive
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biology and because of  difficulty in diagnosis which
leads to delayed treatment.
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